China’s Xinshidai Gastric Cancer Drug Launch Ends Imports From Japan
This article was originally published in PharmAsia News
Executive Summary
Shandong Xinshidai Pharmaceuticals, a subsidiary of Lunan Pharma Group announced March 18 the launch of Weikangda (tegafur, gimeracil, oteracil). Weikangda is developed in China by Xinshida to treat progressive and inoperable gastric cancer. The drug is marked in Japan by Taiho Pharmaceutical under the name TS-1. Chinese patients previously relied on the higher-cost imported drugs from Japan. (Click here for more - Japanese language